Profile data is unavailable for this security.
About the company
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The International Formulations business operates in the generics and branded generics space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, Tolvaptan, Spironolactone, Sertraline, Lamotrigine, and others.
- Revenue in INR (TTM)6.18bn
- Net income in INR706.60m
- Incorporated2007
- Employees1.27k
- LocationRPG Life Sciences LimitedRPG House463, Dr. Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224981650
- Fax+91 2 224970127
- Websitehttps://www.rpglifesciences.com/website/index.php
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 20.06bn | 2.78k | 16.92 | -- | 10.85 | 0.9683 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| SMS Pharmaceuticals Ltd | 7.68bn | 593.38m | 20.26bn | 1.20k | 34.05 | 3.59 | 22.14 | 2.64 | 7.03 | 7.03 | 91.03 | 66.57 | 0.7278 | 1.81 | 4.18 | 6,420,048.00 | 5.55 | 5.43 | 8.40 | 7.33 | 30.10 | 33.30 | 7.62 | 7.87 | 0.7104 | 4.54 | 0.3361 | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 20.26bn | 642.00 | 83.96 | 6.71 | 48.11 | 6.49 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Amrutanjan Health Care Ltd | 4.38bn | 475.20m | 20.39bn | 635.00 | 42.95 | 6.85 | 37.85 | 4.66 | 16.43 | 16.43 | 151.37 | 103.00 | 1.19 | 6.89 | 12.85 | 6,893,025.00 | 12.88 | 16.22 | 16.48 | 20.12 | 50.03 | 53.09 | 10.86 | 13.23 | 3.62 | 217.88 | 0.0074 | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| Panacea Biotec Ltd | 5.50bn | -148.63m | 25.36bn | 1.15k | -- | 3.04 | 127.01 | 4.61 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Themis Medicare Ltd | 4.20bn | 529.90m | 26.48bn | 1.54k | 50.02 | 6.43 | 41.38 | 6.30 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Indoco Remedies Ltd | 17.73bn | 320.40m | 27.63bn | 5.93k | 89.86 | 2.54 | 20.27 | 1.56 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| RPG Life Sciences Limited | 6.18bn | 706.60m | 33.61bn | 1.27k | 47.57 | 8.86 | 37.39 | 5.44 | 42.72 | 42.72 | 373.86 | 229.38 | 1.22 | 1.99 | 8.44 | 4,868,662.00 | 13.92 | 16.07 | 19.35 | 21.77 | 67.85 | 62.99 | 11.43 | 11.99 | 1.45 | 207.32 | 0.00 | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Dishman Carbogen Amcis Ltd | 26.19bn | -1.74bn | 34.26bn | 1.13k | -- | 0.5972 | 38.80 | 1.31 | -11.09 | -11.09 | 166.94 | 365.90 | 0.2661 | 0.6339 | 4.45 | 23,132,690.00 | -1.77 | -0.3986 | -2.21 | -0.4888 | 78.75 | 73.83 | -6.65 | -1.54 | 0.6001 | -0.0583 | 0.3041 | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| Morepen Laboratories Ltd | 17.61bn | 1.31bn | 40.13bn | 1.62k | 28.82 | 3.61 | 25.49 | 2.28 | 2.54 | 2.54 | 34.07 | 20.27 | 1.28 | 4.21 | 6.02 | 10,847,620.00 | 9.56 | 7.90 | 13.28 | 13.34 | 38.57 | 33.34 | 7.48 | 5.49 | 1.99 | 31.88 | 0.0293 | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Gufic BioSciences Ltd | 8.04bn | 849.28m | 40.67bn | 1.45k | 47.84 | 7.08 | 39.87 | 5.06 | 8.48 | 8.48 | 80.23 | 57.26 | 0.7751 | 1.98 | 2.79 | 5,550,852.00 | 8.19 | 11.46 | 12.66 | 19.21 | 53.37 | 45.79 | 10.57 | 10.46 | 1.11 | 7.70 | 0.3401 | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Aarti Drugs Ltd | 23.80bn | 1.52bn | 41.51bn | 1.06k | 27.36 | 3.25 | 20.19 | 1.74 | 16.62 | 16.62 | 259.74 | 139.96 | 0.9954 | 3.16 | 3.43 | 22,364,630.00 | 6.37 | 9.73 | 9.62 | 15.78 | 34.60 | 22.23 | 6.40 | 8.25 | 1.01 | 6.83 | 0.3159 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Solara Active Pharma Sciences Ltd | 12.22bn | -5.36bn | 42.04bn | 2.16k | -- | 2.52 | -- | 3.44 | -137.13 | -137.13 | 320.29 | 301.63 | 0.4731 | 1.77 | 2.69 | 5,667,023.00 | -20.76 | -2.44 | -36.40 | -3.84 | 38.70 | 41.16 | -43.89 | -4.49 | 0.448 | -1.30 | 0.4355 | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Hikal Ltd | 18.21bn | 735.12m | 47.68bn | 2.06k | 64.94 | 3.96 | 24.04 | 2.62 | 5.95 | 5.95 | 147.30 | 97.60 | 0.7509 | 2.37 | 4.27 | 8,837,312.00 | 3.03 | 5.07 | 4.26 | 7.51 | 54.14 | 46.78 | 4.04 | 5.86 | 0.8421 | 2.46 | 0.3919 | 12.19 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
Data as of Nov 22 2024. Currency figures normalised to RPG Life Sciences Limited's reporting currency: Indian Rupee INR
4.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 Oct 2024 | 329.35k | 1.99% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Oct 2024 | 188.33k | 1.14% |
| Union Asset Management Co. Pvt Ltd.as of 31 Oct 2024 | 55.60k | 0.34% |
| Maybank Asset Management Sdn. Bhd.as of 31 Jul 2024 | 42.80k | 0.26% |
| American Century Investment Management, Inc.as of 07 Nov 2024 | 14.50k | 0.09% |
| WhiteOak Capital Asset Management Ltd.as of 31 Oct 2024 | 8.54k | 0.05% |
| Acadian Asset Management LLCas of 30 Sep 2023 | 7.97k | 0.05% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 7.36k | 0.05% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 7.03k | 0.04% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 3.71k | 0.02% |
More ▼
Data from 31 Jul 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
